Literature DB >> 15888746

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer.

V V Kataja1, J Bergh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15888746     DOI： 10.1093/annonc/mdi826

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  13 in total

1.  [Evaluation of biochemical bone metabolism parameters].

Authors:  A Hegele; P Olbert; H G Wahl; R Hofmann
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

2.  Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.

Authors:  Chiara Fuccio; Riccardo Schiavina; Paolo Castellucci; Domenico Rubello; Giuseppe Martorana; Monica Celli; Claudio Malizia; Marta Barios Profitos; Maria Cristina Marzola; Vincenzina Pettinato; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

Review 3.  11C-choline PET/CT and PSA kinetics.

Authors:  Paolo Castellucci; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-12       Impact factor: 9.236

Review 4.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

5.  Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.

Authors:  Francesco Ceci; Ken Herrmann; Paolo Castellucci; Tiziano Graziani; Christina Bluemel; Riccardo Schiavina; Christian Vollmer; Sabine Droll; Eugenio Brunocilla; Renzo Mazzarotto; Andreas K Buck; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-15       Impact factor: 9.236

6.  Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.

Authors:  Vera Graute; Nathalie Jansen; Christopher Ubleis; Michael Seitz; Markus Hartenbach; Michael Karl Scherr; Sven Thieme; Paul Cumming; Katharina Klanke; Reinhold Tiling; Peter Bartenstein; Marcus Hacker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-16       Impact factor: 9.236

7.  (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.

Authors:  Francesco Ceci; Paolo Castellucci; Marcelo Mamede; Riccardo Schiavina; Domenico Rubello; Chiara Fuccio; Valentina Ambrosini; Stefano Boschi; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

Review 8.  Approach to primary care follow-up of patients with prostate cancer.

Authors:  Anna N Wilkinson; Michael D Brundage; Robert Siemens
Journal:  Can Fam Physician       Date:  2008-02       Impact factor: 3.275

9.  [The significance of rebiopsy in the diagnosis of prostate cancer].

Authors:  K-P Braun; S Brookman-Amissah; M May; Y Grassmel; C Heintze; B Hoschke; V Braun
Journal:  Urologe A       Date:  2009-02       Impact factor: 0.639

10.  Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.

Authors:  E Pelosi; V Arena; A Skanjeti; V Pirro; A Douroukas; A Pupi; M Mancini
Journal:  Radiol Med       Date:  2008-04-14       Impact factor: 3.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.